国: イギリス
言語: 英語
ソース: MHRA (Medicines & Healthcare Products Regulatory Agency)
Carvedilol
Genus Pharmaceuticals Ltd
C07AG02
Carvedilol
3.125mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02040000
PACKAGE LEAFLET: INFORMATION FOR THE USER CARVEDILOL 3.125, 6.25, 12.5 AND 25 MG TABLETS READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or pharmacist. This medicine has been prescribed for you only . Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What Carvedilol is and what it is used for 2. WHAT YOU NEED TO KNOW BEFORE you take Carvedilol 3. How to take Carvedilol 4. Possible side effects 5. How to store Carvedilol 6. CONTENTS OF THE PACK AND OTHER information 1. WHAT CARVEDILOL IS AND WHAT IT IS USED FOR Carvedilol belongs to a group of drugs called beta-blockers. Beta-blockers make your blood vessels relax and widen and slows your heart rate, thus causing the heart to beat more calmly and lower blood pressure. Carvedilol is used to: treat angina control high blood pressure. Carvedilol can also be used in combination with other therapies to treat heart failure. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE CARVEDILOL DO NOT TAKE CARVEDILOL IF YOU: are allergic (hypersensitive) to Carvedilol or any of the other ingredients of this medicine (listed in section 6). have a history of asthma or other lung diseases unless you have consulted your doctor or pharmacist first have problems with your heart (for example „heart block‟ or unstable heart failure), as Carvedilol is not suitable for some people with certain types of heart problem have an unusually slow heart beat (<50 bpm) or very low blood pressure (systolic blood pressure below 85 mmHg) sometimes causing dizziness, faintness or lightheadness on standing are receiving verapamil or diltiazem by injection or as an infusion (with a drip) have a problem with the a 完全なドキュメントを読む
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Carvedilol 3.125 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 3.125 mg of carvedilol. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. Light peach, round flat tablet. Scored on one side, debossed on the other side with “CVL” on top and “T1” on bottom. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS _4.1 _ _THERAPEUTIC INDICATIONS _ _CHRONIC HEART FAILURE_ Carvedilol is adjunctive therapy for the treatment of moderate to severe stable chronic heart failure. _HYPERTENSION _ Carvedilol is indicated for the treatment of hypertension. _ANGINA _ Carvedilol is indicated for the prophylactic treatment of stable angina 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The tablets should be taken with fluid. _HYPERTENSION _ Carvedilol may be used for the treatment of hypertension alone or in combination with other antihypertensives, especially thiazide diuretics. Once daily dosing is recommended. _Adults _ The recommended dose for initiation of therapy is 12.5 mg once a day for the first two days. Thereafter the recommended dosage is 25 mg once a day. Although this is an adequate dose in most patients, if necessary the dose may be titrated up to a recommended daily maximum dose of 50 mg given once a day or in divided doses. Dose titration should occur at intervals of at least two weeks. _ _ _Elderly _ An initial dose of 12.5 mg daily is recommended. This has provided satisfactory control in some cases. If the response is inadequate the dose may be titrated up to the recommended daily maximum dose of 50 mg given once a day or in divided doses. _ _ _Paediatric population_ Safety and efficacy in children (under 18 years) has not been established. _ANGINA_ A twice-daily regimen is recommended. _ _ _Adults_ The recommended dose for initiation of therapy is 12.5 mg twice a day for the first two days. Thereafter, the recommend 完全なドキュメントを読む